Monoclonal antibody therapy for lymphoma (Q35158950)

6 August 2017

1 reference

title

Monoclonal antibody therapy for lymphoma (English)

1 reference

6 August 2017

1 reference

Peter Campbell

1 reference

6 August 2017

Robert Marcus

series ordinal

1 reference

6 August 2017

publication date

1 September 2003

1 reference

6 August 2017

1 reference

inferred from page(s)

published in

Blood Reviews

1 reference

6 August 2017

1 reference

6 August 2017

1 reference

6 August 2017

page(s)

143-152

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Rituximab: mechanism of action and resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Immunochemotherapy in indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Low- versus high-dose interferon alfa-2a in relapsed indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Rituximab in the treatment of diffuse large B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK).

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Rituximab: enhancing stem cell transplantation in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Rituximab dose-escalation trial in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

A murine xenograft model for human CD30+ anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1)

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Improving outcomes in transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

Pharmacokinetics of CAMPATH-1H in BMT patients

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2803%2900005-5

7 January 2021

10.1016/S0268-960X(03)00005-5

Identifiers

DOI

1 reference

release_lj5dbhz5kvgcvo7zvwgtzikr24

6 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lj5dbhz5kvgcvo7zvwgtzikr24

24 November 2022

mapped directly with Wikidata item

1 reference